GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (FRA:TGNA) » Definitions » Research & Development

Transgene (FRA:TGNA) Research & Development : €29.44 Mil (TTM As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Transgene Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Transgene's Research & Development for the six months ended in Jun. 2024 was €15.42 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was €29.44 Mil.

Transgene Research & Development Historical Data

The historical data trend for Transgene's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene Research & Development Chart

Transgene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.39 27.35 32.88 32.17 29.59

Transgene Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.97 15.19 15.57 14.02 15.42

Transgene Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €29.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgene  (FRA:TGNA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Transgene Research & Development Related Terms

Thank you for viewing the detailed overview of Transgene's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Transgene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (FRA:TGNA) » Definitions » Research & Development
Comparable Companies
XPAR:IVA XPAR:MAAT XPAR:IPH XPAR:ADOC XPAR:DBV XPAR:ALCLS XPAR:AELIS XPAR:ABNX XPAR:NANO XPAR:SIGHT VRTX REGN ASX:CSL XKRX:207940 XBRU:UCB ALNY XBRU:ARGX XKRX:068270 BNTX BGNE
Traded in Other Exchanges
0OCQ:UK TNG:France
Address
400 Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, FRA, 67400
Website
https://www.transgene.fr
Transgene SA is a biotechnology company. The Company conducts its business exclusively in the clinical research and development of therapeutic vaccines and immunotherapeutic products. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products. The majority of its operations is located in France.